News | PET-CT | June 09, 2017

Toshiba Medical’s New Celesteion PET/CT Improves Resolution, Reconstruction

Offers Patient Comfort and Safety

Toshiba Medical launches its new Celesteion PUREViSION Edition PET/CT system to help diagnose and treat oncology patients

Toshiba Medical launches its new Celesteion PUREViSION Edition PET/CT system to help diagnose and treat oncology patients.

Oncologists have access to advanced imaging technologies for excellent cancer patient care with the new Celesteion PUREViSION Edition PET/CT system from Toshiba Medical, a Canon Group company. The newest edition of Celesteion allows for ease and efficiency in PET/CT, CT simulation and diagnostic CT exams, to help diagnose and treat oncology patients. The system’s patient-centered design can help deliver a safe and comfortable experience, facilitating better patient compliance.

The Celesteion PUREViSION Edition presents a significant advancement in PET/CT resolution and reconstruction. Offering 70 cm true field-of-view, as well as Toshiba Medical’s SUREFLiGHT reconstruction technology, including Point Spread Function and Time of Flight techniques, the system offers oncologists sharp images and high contrast for improved visualization of small tumors throughout the body. The system’s PUREViSION 16-row CT detector assists in acquiring high-quality CT images, while SEMARTM helps reduce artifacts caused by metal implants, allowing providers to view more clinical information.

Prioritizing patient comfort, the Celesteion PUREViSION Edition features an industry-leading 90 cm wide CT bore that creates a sense of openness to put patients at ease and offers versatile positioning for optimal treatment planning. Ensuring clinicians don’t have to choose between efficiency and safety, the system also comes standard with AIDR 3D iterative dose reduction technology.

“We developed the Celesteion PUREViSION Edition with our customers’ needs in mind,” said Dominic Smith, senior director, CT, PET/CT, and MR Business Units, Toshiba America Medical Systems, Inc. “Accuracy is everything when treating oncology patients and Toshiba Medical is committed to providing our customers with the high-quality imaging solutions they require to provide efficient, effective patient care.”

Toshiba Medical will showcase the Celesteion PUREViSION Edition at this year’s Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting in Denver, June 10–14, 2017.

For more information: www.medical.toshiba.com

Related Content

News | PACS | June 23, 2017
Medidata and Median Technologies announced a new collaboration to streamline the growth and use of medical imaging in...
RamSoft Partners With Gamel to Enhance Patient Care in Peruvian Market
News | PACS | June 23, 2017
RamSoft announced a new partnership with Peru-based medical imaging equipment provider, Gamel. With RamSoft’s...
ClearRead CT Nearing 50 Installations Milestone
News | Computed Tomography (CT) | June 22, 2017
June 22, 2017 — Riverain Technologies announced that it is now processing data from nearly 50...
RadNet Inc. Acquires Equity Stake in Medic Vision
News | Radiation Dose Management | June 21, 2017
June 21, 2017 — RadNet Inc. and Medic Vision Imaging Solutions Ltd.
Diagnostic Radiation Exposure Safe for Children, Experts State
News | Pediatric Imaging | June 21, 2017
In an article published in the June 2017 issue of The Journal of Nuclear Medicine, researchers assert that exposure to...
Carestream Showing New Mobile X-ray System With Carbon Nanotube Technology at AHRA
News | Digital Radiography (DR) | June 20, 2017
June 20, 2017 — Carestream Health will show the DRX-Revolution Nano Mobile...
Dual-Agent PET/MR With Time of Flight Detects More Cancer

Tc-99m MDP bone scan (left) is negative for osseous lesions. NaF/FDG PET/MRI (right and second slide) confirms absence of bone metastases, but shows liver metastases. Image courtesy of Stanford University.

News | PET-MRI | June 20, 2017
Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (...
Combined Optical and Molecular Imaging Could Guide Breast-Conserving Surgery

WLE specimen from a patient with a grade 3, ER-/HER2-, no special type (NST) carcinoma. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov signal. An increased signal from the tumor is visible (white arrows); mean radiance is 871 ± 131 photons/s/cm2/sr, mean TBR is 3.22. Both surgeons measured the posterior margin (outlined in blue) as 2 mm (small arrow); a cavity shaving would have been performed if the image had been available intraoperatively. The medial margin (outlined in green) measured >5 mm by both surgeons. Pathology ink prevented assessing the lateral margin; a phosphorescent signal is visible (open arrows). (C) Specimen radiography image. The absence of one surgical clip to mark the anterior margin, and the odd position of the superior margin clip (white arrow) prevented reliable margin assessment. (D) Combined histopathology image from two adjacent pathology slides on which the posterior margin (bottom of image) and part of the primary tumor are visible (open arrows). The distance from the posterior margin measured 3 mm microscopically (double arrow). The medial margin is > 5 mm (not present in image). Credit: A. D. Purushotham, M.D., King’s College London, UK

News | Nuclear Imaging | June 20, 2017
June 20, 2017 — Breast-conserving surgery (BCS) is the primary treatment for early-stage...
Fujifilm Exhibits Suite of Enterprise Imaging Solutions at SIIM 2017
News | Enterprise Imaging | June 19, 2017
Fujifilm Medical Systems U.S.A. Inc. presented its comprehensive Synapse Enterprise Imaging portfolio at the 2017...
The Magnetom Vida with BioMatrix technology
News | Magnetic Resonance Imaging (MRI) | June 16, 2017
The U.S. Food and Drug Administration (FDA) has cleared the Magnetom Vida 3 Tesla (3T) magnetic resonance imaging (MRI...
Overlay Init